JAK1 and prostate carcinoma: JAK mutations, such as TYK2 mutations in malignant peripheral nerve sheath tumours (approximately 60%) and acute leukaemia (approximately 40%) and JAK1 mutations in acute leukaemia (27.3%) and certain subtypes of prostate cancer (68%) could inhibit the IFN-I signals and even reverse the biological effect [224–227].